New combination treatment for advanced pancreatic cancer
Official title: TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
Funded at University of California at Davis · NIH-11009524 · Data updated 2026-11-12
This study is testing a new treatment for advanced pancreatic cancer that combines a promising chemotherapy drug with immune boosters to help your body fight the cancer better, and you might have a chance to join the trial if you're interested!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $572,502 |
| NIH project number | 5R01CA269233-03 |
| Project ID | NIH-11009524 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced pancreatic ductal adenocarcinoma who have not responded to standard treatments.
✕Less likely to help
Patients with early-stage pancreatic cancer or those who have not been diagnosed with pancreatic cancer may not benefit from this research.
What this research studies
This research aims to develop a novel treatment strategy for advanced pancreatic cancer by combining a new chemotherapy drug, TGX-1214, with immune checkpoint inhibitors. The approach utilizes a nanoemulsion formulation of DHA-SBT-1214, which has shown promising results in preclinical models by significantly reducing tumor growth. The study will involve a multidisciplinary team from the University of California at Davis and other institutions, focusing on enhancing the immune response against pancreatic tumors. Patients may have the opportunity to participate in trials that explore this innovative treatment combination.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced pancreatic cancer.
How similar studies have gone: Other research has shown success with similar combination therapies in treating various cancers, indicating potential for this approach in pancreatic cancer as well.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Mackenzie, Gerardo Guillermo — University of California at Davis
- Study coordinator: Mackenzie, Gerardo Guillermo
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.